ulcerative colitis
Conditions
Interventions
Combination group:Biolosion plus mesalazine
Sponsors
The Sixth Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Patients with mild to moderate UC(Mayo Clinic score 3-10) 2) Patients were diagnosed by clinical manifestations, laboratory examinations, imaging, endoscopy, and histopathology; 3) No gender limitation, and the range of age between 18-70; 4) UC confirmed by colonoscopy and histology was active for more than 1 week; 5) The length of the lesion was =15cm under colonoscopy.
Exclusion criteria
Exclusion criteria: 1) More than moderate disease activity; 2) Hemoglobin < 80g/L; 3) Active intestinal infection; 4) Antibiotic use within the past 2 weeks or a change in an oral dose of 5-aminosalicylic acid (5-ASA) within the past 4 weeks, rectal use of 5-ASA within 7 days prior to study entry or Steroids; 5) lactating women and pregnant women; 6) Patients receiving any investigational drug or taking commercially available probiotic preparations within 3 months; 7) Patients with obvious liver, kidney, endocrine, respiratory, neurological, or cardiovascular diseases; 8) A history of atypical hyperplasia of the colon or any cancer within 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mayo Clinic score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factor;Laboratory examination index;imageological examination;Intestinal flora; | — |
Countries
China
Contacts
Public ContactXiang Gao
The Sixth Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed